5 year image

Rolling out overall survival results at 56 months for frontline DARZALEX® + Rd triplet treatment1*

See OS data
subgroup image

Primary progression-free survival results from the MAIA trial, as well as a subgroup and post hoc analysis

Explore data analysis
video icon image

Administration options include intravenous DARZALEX® and subcutaneous DARZALEX FASPRO®1,2†

View ~3 to 5 minute SC administration

After 56 months: 32% reduction in the risk of death with DRd vs Rd alone in the MAIA trial (HR=0.68; 95% CI: 0.53, 0.86; P=0.0013; mOS not reached in either arm).1*

*Median follow-up was 56 months in the DRd group (range: 53.0-60.1 months) and in the Rd group (range: 52.5-59.4 months).1,3

†DARZALEX FASPRO® is administered by subcutaneous injection over approximately 3 to 5 minutes. In contrast, DARZALEX® is administered by intravenous infusion over approximately 7, 4, and 3 hours for first, second, and subsequent infusions, respectively.1,2  View IV administration

CI=confidence interval; DRd=DARZALEX® (D) + lenalidomide (R) + dexamethasone (d); HR=hazard ratio; IV=intravenous; mOS=median overall survival; Rd=lenalidomide (R) + dexamethasone (d); SC=subcutaneous.

References:

  1. DARZALEX® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  2. DARZALEX FASPRO® [Prescribing Information]. Horsham, PA: Janssen Biotech, Inc.
  3. Facon T, Kumar SK, Plesner T, et al. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(11):1582-1596.